Skip to main content
SpringerLink
Log in

Effizienz antidiabetischer Kombinationstherapien bei nichtalkoholischer Fettlebererkrankung und Typ‑2‑Diabetes

Efficiency of antidiabetic combinatorial treatment in non-alcoholic fatty liver disease and type 2 diabetes

  • Journal Club
  • Published:
Der Diabetologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA (2003) Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52(6):1364–1370

    Article  CAS  PubMed  Google Scholar 

  2. Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, Chevallier O, Duvillard L, Vergès B (2017) Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD Study. J Clin Endocrinol Metab 102(2):407–415

    PubMed  Google Scholar 

  3. Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, Bansal B, Kaur P, Jevalikar G, Gill HK, Choudhary NS, Mithal A (2018) Effect of Empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 41(8):1801–1808

    Article  PubMed  Google Scholar 

  4. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN, LEAN Trial Team (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679–690

    Article  CAS  PubMed  Google Scholar 

  5. Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt A, Hooker J, Haufe W, Hooker C, Brenner DA, Sirlin CB, Loomba R (2016) Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 65(2):369–376

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Davis TME, Mulder H, Lokhnygina Y, Aschner P, Chuang LM, Raffo Grado CA, Standl E, Peterson ED, Holman RR, TECOS Study Group. (2018) Effect of race on the glycaemic response to sitagliptin: insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metab 20(6):1427–1434

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für klinische Diabetologie, Deutsches Diabetes-Zentrum an der Heinrich-Heine-Universität, Leibniz-Zentrum für Diabetesforschung, Auf’m Hennekamp 65, 40225, Düsseldorf, Deutschland

    S. Kahl

Authors
  1. S. Kahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Kahl.

Ethics declarations

Interessenkonflikt

S. Kahl gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kahl, S. Effizienz antidiabetischer Kombinationstherapien bei nichtalkoholischer Fettlebererkrankung und Typ‑2‑Diabetes. Diabetologe 14, 601–602 (2018). https://doi.org/10.1007/s11428-018-0422-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-018-0422-z

Search

Navigation